Regeneron Pharmaceuticals is pursuing FDA approval for its antibody cocktail to be used as a preventative treatment for COVID-19 after its latest study showed positive results. The company announced in a release that its phase three prevention trial for REGEN-COV—a combination of casirivimab and imdevimab—showed that the drug reduced the risk of symptomatic infections by 81 percent. The findings are drawn from the 1,505 people who were not infected when they entered the trial. The double-blind, placebo-controlled trial also found that the drug cocktail “rapidly protected” people from exposure to the CCP (Chinese Communist Party) virus in households where someone else has the virus. It provided 72 percent protection against symptomatic infections in the first week and 93 percent after that, the company announced. Among people who developed symptoms of COVID-19, the disease caused by the CCP virus, those who were treated with REGEN-COV cleared the virus faster and their symptoms were …